<DOC>
	<DOCNO>NCT00469859</DOCNO>
	<brief_summary>RATIONALE : Lestaurtinib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , cytarabine idarubicin , work different way stop growth cancer cell , either kill cell stop divide . Giving lestaurtinib together cytarabine idarubicin may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose lestaurtinib give together cytarabine idarubicin see well work treat young patient relapse refractory acute myeloid leukemia .</brief_summary>
	<brief_title>Lestaurtinib , Cytarabine , Idarubicin Treating Younger Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safe , tolerable , biologically active dose lestaurtinib combination chemotherapy comprise cytarabine idarubicin young patient relapse refractory FLT3-mutant acute myeloid leukemia . Secondary - Determine overall response rate patient treat regimen . - Optimize dose lestaurtinib base primarily biologic activity rather toxicity . - Correlate clinical response regimen ability achieve adequate FLT3 plasma inhibitory activity level vitro sensitivity pretreatment leukemic cell lestaurtinib patient . - Determine mechanism resistance lestaurtinib patient . - Assess feasibility use rapid central determination FLT3 mutation status study entry determine induction therapy future upfront protocol . OUTLINE : This multicenter , dose-finding study lestaurtinib follow efficacy study . - Dose-finding phase : - Course 1 : Patients receive cytarabine IV 2 hour twice daily day 1-4 , idarubicin IV 15 minute day 2-4 , oral lestaurtinib twice daily day 5-28 . Patients achieve complete partial response proceed course 2 . Cohorts 6 patient receive escalate dos lestaurtinib tolerable biologically active dose ( TBAD ) determine . The TBAD define dose 2 6 patient experience DLT biologic activity confirm plasma inhibitory activity ( PIA ) assay . - Course 2 : Patients receive high-dose cytarabine IV 3 hour twice daily day 1-4 oral lestaurtinib ( dose determine course 1 ) twice daily day 5-28 . Patients achieve complete partial response proceed continuation therapy . - Continuation therapy : Patients receive oral lestaurtinib twice daily day 1-28 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . - Efficacy phase : Once TBAD determine , subsequent patient receive treatment course 1 2 lestaurtinib TBAD . Patients may also receive continuation therapy dose-finding phase . Blood sample collect periodically study treatment pharmacokinetic PIA assay . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 37 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) accord FAB classification At least 5 % blast bone marrow , without extramedullary disease In first relapse induction therapy OR refractory induction therapy ≤ 1 attempt remission induction Patients first relapse &gt; 1 year initial diagnosis AML exclude dosefinding phase study , eligible efficacy phase First relapse hematopoietic stem cell transplantation ( HSCT ) allow provide patient evidence active graftversushost disease ( GVHD ) least 4 month posttransplantation Positive FLT3 activate mutation ( internal tandem duplication kinase domain point mutation ) use standard polymerase chain reactionbased procedure time course illness Treatmentrelated AML allow PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 50100 % ( &gt; 16 year age ) OR Lansky PS 50100 % ( ≤ 16 year age ) Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR serum creatinine base age gender follow : Creatinine great 0.4 mg/dL ( 1 month &lt; 6 month age ) Creatinine great 0.5 mg/dL ( 6 month &lt; 1 year age ) Creatinine great 0.6 mg/dL ( 1 year &lt; 2 year age ) Creatinine great 0.8 mg/dL ( 2 year &lt; 6 year age ) Creatinine great 1 mg/dL ( 6 year &lt; 10 year age ) Creatinine great 1.2 mg/dL ( 10 year &lt; 13 year age ) Creatinine great 1.4 mg/dL ( female ) 1.5 mg/dL ( male ) ( 13 year &lt; 16 year age ) Creatinine great 1.4 mg/dL ( female ) 1.7 mg/dL ( male ) ( 16 year age ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT &lt; 5 time ULN ( unless relate leukemic involvement ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Shortening fraction ≥ 27 % echocardiogram OR ejection fraction ≥ 50 % radionuclide angiogram PRIOR CONCURRENT THERAPY : Recovered prior therapy No prior cumulative anthracycline dos exceed 450 mg/m^2 daunorubicin equivalent Patients relapse receive treatment protocol COGAAML03P1 COGAAML0531 ( 300 mg/m^2 daunorubicin hydrochloride 48 mg/m^2 mitoxantrone hydrochloride ) allow provide received additional anthracyclines At least 14 day since prior cytotoxic therapy Hydroxyurea allow decrease WBC prior start protocol treatment No concurrent hydroxyurea At least 7 day since prior biologic agent At least 14 day since prior monoclonal antibody therapy Radiotherapy chloromas allow Irradiated lesion may use assess tumor response No concurrent chemotherapy , investigational therapy , immunomodulating agent , steroid Steroids use antiemetic allow Prophylactic intrathecal cytarabine allow No concurrent CYP3A4,5 inhibitor , include follow : Azole antifungal ( e.g. , fluconazole voriconazole ) Cyclosporine Erythromycin Clarithromycin Troleandomycin HIV protease inhibitor Nefazodone No concurrent CYP3A4,5 inducer , include follow : Carbamazepine Dexamethasone Rifampin Phenobarbital Phenytoin Hypericum perforatum ( St. John 's wort )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>